“We serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.” – Edward Kliphuis, Partner, Sofinnova

Sofinnova Partners, a prominent European life sciences venture capital firm with offices in Paris, London, and Milan, has successfully concluded the fundraising for Sofinnova Digital Medicine I, amassing a total of $200 million (€190M), surpassing its initial target. Spearheaded by Partners Edward Kliphuis and Simon Turner, this fund is dedicated to supporting innovative entrepreneurs at the intersection of biology, data, and computation.

According to Antoine Papiernik, Chairman and Managing Partner of Sofinnova, the new digital medicine fund comes at a pivotal moment as the healthcare sector undergoes a significant transformation due to digital advancements. It focuses on three key areas: enabling technologies, analytics, and treatment, offering financial support, expertise, and extensive healthcare networks to entrepreneurs. (Businesswire)

Since its inception, it has already invested in five highly innovative companies. Two recent additions to the portfolio are L’école AI, which simplifies deep-learning systems for life sciences, and Betteromics, a platform unifying health and omics data.

Edward Kliphuis said the fund was successfully investing in companies fusing state-of-the-art computational methods with advanced biological innovations.

Sofinnova Partners, with over 50 years of experience, is deeply established in the European venture capital landscape, having backed over 500 companies and managing over €2.5 billion. The successful closing of Sofinnova Digital Medicine I underscores the firm’s dedication to shaping the future of healthcare.

Related Story: Rapport Therapeutics Raises $150 Million For Precision Neuromedicines